600572.SH
康恩贝
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.21
−2.55%Year over year
Reported trailing growth
- Revenue
- +5.0%
- EBITDA
- —
- EBIT
- -8.4%
- EPS
- -19.8%
- Free cash flow
- +17.2%
- Operating cash flow
- +1.1%
Forward estimates
Based on analyst estimates
- Revenue
- -77.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +2.6%
- EBITDA
- +5.0%
- EBIT
- +3.8%
- Net income
- +9.8%
- EPS
- +10.7%
- Free cash flow
- -2.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026